Halloween Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Chris Blumas
Alcon IncALCBUY ON WEAKNESSOct 15, 2025
Chris BlumasUnknown
N/A
Stock price when the opinion was issued
$63.15
As of Oct 13, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
European-based, but US operating platform. Contact lenses + surgical supplies (corrective procedures), each with 50% of revenues. Demographics is supportive even of eye health, and increased screen time also feeds into that. Reasonable valuation at 17x PE, 4-5% FCF yield.
Attractive, defensive business in this environment. Yield is 0.57%.
Chris BlumasOwned
biotechnologypharmaceutical
TOP PICK
Proad product array. Not widely followed. Very strong grower.
Thomas GalvinOwned
biotechnologypharmaceutical
Medical devices are the one area he's been willing to be in. He likes ABT as a diversified medical device player. Another go-to name is ALC, which focuses on eye health.